Pathstone Family Office’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $15.2M | Buy |
453,685
+263,705
| +139% | +$9.33M | 0.12% | 123 |
|
|
2023
Q2 | $7.21M | Buy |
189,980
+102
| +0.1% | +$3.97K | 0.1% | 136 |
|
|
2023
Q1 | $8.04M | Sell |
189,878
-360,266
| -65% | -$15.6M | 0.13% | 108 |
|
|
2022
Q4 | $24.2M | Buy |
550,144
+128,447
| +30% | +$6.16M | 0.21% | 85 |
|
|
2022
Q3 | $18.8M | Buy |
421,697
+342,418
| +432% | +$16.6M | 0.17% | 77 |
|
|
2022
Q2 | $4.16M | Buy |
79,279
+30,285
| +62% | +$1.54M | 0.09% | 122 |
|
|
2022
Q1 | $2.76M | Buy |
48,994
+11,595
| +31% | +$602K | 0.06% | 142 |
|
|
2021
Q4 | $2.21M | Buy |
37,399
+3,137
| +9% | +$155K | 0.06% | 177 |
|
|
2021
Q3 | $1.47M | Buy |
34,262
+7,228
| +27% | +$320K | 0.04% | 213 |
|
|
2021
Q2 | $1.06M | Buy |
27,034
+7,019
| +35% | +$273K | 0.03% | 259 |
|
|
2021
Q1 | $725K | Buy |
20,015
+889
| +5% | +$31.6K | 0.02% | 269 |
|
|
2020
Q4 | $703K | Buy |
19,126
+15,176
| +384% | +$557K | 0.03% | 140 |
|
|
2020
Q3 | $139K | Buy |
3,950
+756
| +24% | +$26.5K | 0.02% | 234 |
|
|
2020
Q2 | $100K | Sell |
3,194
-1,057
| -25% | -$35.9K | 0.01% | 230 |
|
|
2020
Q1 | $131K | Buy |
+4,251
| New | +$145K | 0.02% | 200 |
|
|
2019
Q4 | – | Sell |
-544
| Closed | -$18K | – | 569 |
|
|
2019
Q3 | $18K | Sell |
544
-13,376
| -96% | -$486K | ﹤0.01% | 405 |
|
|
2019
Q2 | $573K | Sell |
13,920
-226
| -2% | -$8.97K | 0.07% | 122 |
|
|
2019
Q1 | $570K | Buy |
+14,146
| New | +$567K | 0.07% | 107 |
|
|
2018
Q2 | – | Sell |
-575
| Closed | -$19K | – | 283 |
|
|
2018
Q1 | $19K | Sell |
575
-237
| -29% | -$8.15K | 0.01% | 164 |
|
|
2017
Q4 | $28K | Sell |
812
-22
| -3% | -$750 | 0.02% | 80 |
|
|
2017
Q3 | $29K | Sell |
834
-8,695
| -91% | -$279K | 0.03% | 89 |
|
|
2017
Q2 | $304K | Sell |
9,529
-602
| -6% | -$19K | 0.13% | 74 |
|
|
2017
Q1 | $328K | Sell |
10,131
-3,009
| -23% | -$94.9K | 0.18% | 63 |
|
|
2016
Q4 | $405K | Buy |
13,140
+10,781
| +457% | +$329K | 0.26% | 51 |
|
|
2016
Q3 | $76K | Sell |
2,359
-693
| -23% | -$23.2K | 0.08% | 48 |
|
|
2016
Q2 | $101K | Buy |
3,052
+5
| +0.2% | +$160 | 0.1% | 38 |
|
|
2016
Q1 | $86K | Buy |
3,047
+2,931
| +2,527% | +$83.7K | 0.17% | 35 |
|
|
2015
Q4 | $4K | Sell |
116
-98
| -46% | -$3.08K | 0.02% | 75 |
|
|
2015
Q3 | $6K | Buy |
214
+100
| +88% | +$3.21K | 0.02% | 117 |
|
|
2015
Q2 | $4K | Buy |
114
+1
| +0.9% | +$33 | 0.01% | 110 |
|
|
2015
Q1 | $4K | Buy |
113
+1
| +0.9% | +$32 | 0.01% | 110 |
|
|
2014
Q4 | $3K | Sell |
112
-917
| -89% | -$26.3K | 0.01% | 97 |
|
|
2014
Q3 | $29K | Buy |
1,029
+919
| +835% | +$25.8K | 0.09% | 85 |
|
|
2014
Q2 | $3K | Buy |
110
+1
| +0.9% | +$29 | 0.01% | 124 |
|
|
2014
Q1 | $3K | Buy |
109
+1
| +0.9% | +$30 | 0.01% | 146 |
|
|
2013
Q4 | $3K | Sell |
108
-4,574
| -98% | -$133K | 0.01% | 185 |
|
|
2013
Q3 | $127K | Sell |
4,682
-1,053
| -18% | -$28.7K | 0.55% | 24 |
|
|
2013
Q2 | $152K | Buy |
+5,735
| New | +$158K | 0.18% | 31 |
|
Other funds holding PFE
Pathstone Family Office's PFE Position: Q3 2023 in Review
Pathstone Family Office increased its Pfizer (PFE) stake by 139% in Q3 2023, buying an estimated $9.33M and bringing the position to 453,685 shares worth $15.2M. The position accounts for 0.12% of the portfolio, ranked #123.
Pathstone Family Office first reported a position in PFE in Q2 2013 and has held it in 38 quarters since. The position peaked at $24.2M in Q4 2022. 2,925 funds tracked by Wall St. Rank hold PFE as of Q3 2023.
- Pathstone Family Office held 453,685 shares of Pfizer worth $15.2M as of Q3 2023.
- Pathstone Family Office bought 263,705 Pfizer shares in Q3 2023, an estimated $9.33M.
- Pfizer made up 0.12% of Pathstone Family Office's portfolio in Q3 2023, its #123 holding.
- Pathstone Family Office first reported a position in Pfizer in Q2 2013 and has held it in 38 quarters since.
- Pathstone Family Office's Pfizer position peaked at $24.2M in Q4 2022.
- 2,925 funds tracked by Wall St. Rank held Pfizer as of Q3 2023.
Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.